Contract Manufacturing, Biopharmaceutical Production

Merck KGaA Acquires CDMO Exelead

January 11, 2022

The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.

Piramal Pharma Invests Minority Stake in India-Based CDMO, Yapan Bio

January 05, 2022

With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.

FUJIFILM Irvine Scientific Opens New European Manufacturing Facility

December 16, 2021

FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.

FUJIFILM Diosynth Biotechnologies to Create Major Biopharma Manufacturing Site in United Kingdom

December 16, 2021

FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.

Lonza and Bioqube Ventures Form Agreement for Future Development and Manufacture of Biologics and Small Molecules

December 09, 2021

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.

Leucid Bio to Use Lonza’s Cocoon Platform for Automated Manufacturing of CAR T Cells

December 09, 2021

Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.

Sartorius to Invest in Growing Operations in France

December 02, 2021

Sartorius is investing €100 million (US$113 million) between 2021 and 2025 to expand capacities for production, innovation, and storage at its French facilities in Aubagne, Cergy, and Lourdes.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

November 29, 2021

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

Avid Bioservices Expands into Viral Vector Development and Manufacturing Services

October 14, 2021

Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California.

AGC Bio Boosts Manufacturing Capacity for pDNA and mRNA at Heidelberg Facility

September 14, 2021

AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.